Skip to content

A survey of clinical efficacy observation:combined with Qiangxin mixture for vulnerable phase of patients

A survey of clinical efficacy observation:combined with Qiangxin mixture for vulnerable phase of patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003980
Enrollment
Unknown
Registered
2020-08-26
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

Sponsors

Shanghai Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Voluntarily sign the informed consent and perform their duties; (2) Discharged patients who meet the diagnostic criteria and participate in the test voluntarily during their stay in hospital; (3) The condition is relatively stable and can be discharged from hospital and followed up; (4) in patients with cardiac function II ~ III level; (5) The age of the patient is >= 45 and <= 85 years of age, regardless of gender; Only those who meet the above criteria can be included in the observed cases. None of them is necessary.

Exclusion criteria

Exclusion criteria: (1) Patients with failure of lung, liver, kidney and other important organs, namely heart failure caused by non-cardiac origin; (2) Patients with congenital heart disease, constrictive pericarditis, severe pulmonary hypertension, obvious valvular disease, patients requiring cardiac resynchronization therapy; (3) Patients with severe primary medical diseases such as liver, kidney and hematopoietic system; (4) persons with mental or legal disabilities; (5) Have participated in or will participate in other drug clinical studies; (6) Living a bad life, such as being a chronic alcoholic or a drug addict; (7) pregnant and lactating women; (8) As judged by the researcher, it is not suitable to participate in this experiment; Those who meet 1 of the above conditions cannot be taken as subjects.

Design outcomes

Primary

MeasureTime frame
MLFHQ;The six-minute walk is the test distance (6MWT);Left ventricular ejection fraction (LVEF);Blood pressure;Heart rate;N terminal pro B type natriuretic peptide (NT-pro-BNP);Left ventricular end-diastolic diameter (LVEDD);Ventricular remodeling parameter;

Countries

China

Contacts

Public ContactZhaoshan Chen

Shanghai Hospital of Traditional Chinese Medicine

czshan123@sina.com+86 15618002017

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026